Pharma comms should forget its social media FOMO and realize that they’re the gold standard
Appropriately for an event held over Valentine’s Day, PRWeek’s inaugural PharmaComms event reflected its audience’s ongoing love affair with social media.
Social Media
Sermo receives investment from private equity firm Abry Partners
Abry is now the sole investor in the social platform for doctors.
Eugene the Egg revealed as ‘cracking campaign’ for mental health
The mystery behind one of the hottest Insta stars to emerge on the social media platform has finally been broken. PR pros wade in to Eugene’s eggcellent campaign.
To recruit for clinical trials, throw out the usual ad playbook: study
New research on what attracts patients to volunteer for clinical trials was presented at Digital Pharma East in Philadelphia. The windup: be transparent.
Why pharma should start paying more attention to Instagram
Facebook Health’s Danielle Salowski and Merck’s Nancy Nolan shared best practices for Instagram at Digital Pharma East in Philadelphia.
The status of online health communities post-Cambridge Analytica
For many online health communities, the Facebook-Cambridge Analytica scandal didn’t have a significant impact, and members still see the social network as an invaluable resource.
Twitter follows Facebook in share price plunge as monthly active users fall
Despite some other positive indicators, Twitter’s share price fell 14% as the platform revealed a dip in its monthly active users in its second quarter results, compared to the previous quarter.
Twitter purge of locked accounts welcomed by Unilever’s Keith Weed
Some Twitter accounts could lose millions of followers when the social platform purges large numbers of “locked” accounts this week.
Biogen, MyMSTeam social network launch patient education resource
The goal of the product is to educate MS patients about the effect the disease has on cognition.
Kim Kardashian deletes Instagram post promoting morning sickness drug
Kardashian’s previous posts for Duchesnay’s morning sickness treatments were slammed by the FDA for not including side effects or risk information.
